FWB 1901
Alternative Names: FWB-1901Latest Information Update: 13 Oct 2021
At a glance
- Originator Shenzhen Forward Pharmaceutical
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 12 Oct 2021 Preclinical trials in Cancer in China (Parenteral) (Shenzhen Forward Pharmaceutical pipeline, October 2021)